Rockville, Md. The global melanoma cancer diagnostics market is set to grow at over 7% CAGR and surpass US$ 853.5 Mn by 2022, according to Fact.MR, with North America and Europe the most lucrative regions. Rising melanoma prevalence and a steady stream of research into cancer detection and management are pulling the market forward, alongside more effective immunotherapies.
BRAF mutation testing leads by type and hospital-associated labs handle the largest share of work. The United States anchors demand, while several European markets grow quickly off a smaller base.
Tests, Settings and Regions
BRAF mutation testing accounts for a significant share of global revenue and stays widely used across North America and Europe. The faster growth belongs to circulating tumour cell testing, which outpaces BRAF, while immunohistochemistry expands at over 6% CAGR. By setting, hospital-associated labs are the most prominent end user and are expected to stay the largest, with independent diagnostic laboratories holding steady, passing US$ 100 Mn in North America by 2022 and growing at close to 8% in Europe, alongside cancer research institutes.
The United States grows at over 7% CAGR to reach US$ 409.2 Mn by 2022, Germany advances at 7.4% CAGR as one of Europe's largest markets, and the United Kingdom grows faster than Germany while remaining smaller in size.
Research and Immunotherapy Drive Growth
The momentum is clinical. Rising prevalence, expanding R&D into diagnosis and management, and the arrival of effective immunotherapies are together lifting demand. The outlook is positive, though limited funding in emerging countries and regulatory hurdles could slow progress over the forecast period.
Suppliers and Their Playbook
The field is led by molecular and genomic diagnostics specialists.
- Cancer Genetics, Inc., Myriad Genetics Inc., Abbott Laboratories, Foundation Medicine, Inc., and Pathway Genomics Corporation are among the leading companies profiled in the report.
Reading the Market for Decisions
For diagnostics firms, BRAF and fast-rising CTC testing mark where to focus. Investors get a market with a firm clinical tailwind. Procurement and lab teams can plan around hospital labs leading demand and North America and Europe carrying the largest opportunity through 2022.
About the Report
Fact.MR's study covers the global melanoma cancer diagnostics market for the 2017 to 2022 forecast period, with segmentation by test type, end user and region. It sizes each segment, maps the competitive field, and weighs the clinical forces shaping demand. Further detail is available in the melanoma cancer diagnostics market report.
About Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.